Novartis reported positive Phase III RemIND trial results for remibrutinib in chronic inducible urticaria, showing higher complete response rates than placebo and moving closer to the first targeted therapy for CIndU.
In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Shishir Agarwal, President and Managing Director, Terumo India, discusses how MedTech companies are adapting their products and strategies to meet the growing de
.png)
The USFDA has completed its inspection of Enzene’s manufacturing unit in Chakan, Pune, issuing six procedural observations with no data integrity issues. The outcome strengthens the company’s compliance standing in regulated markets.
.png)
Mankind Pharma has completed a multi-year transformation of its global supply chain and procurement operations, cutting stock-outs by 75% and strengthening medicine access across 25+ international markets with AI-powered planning tools.
.jpeg)
Thermo Fisher partners with Datavant to enhance clinical research by connecting real-world data (RWD) and speeding up evidence generation for biotech and pharma companies.
Cipla Foundation and IISc have launched a Centre for Pulmonary Medicine in Bengaluru, offering advanced care, research, and training to tackle India’s rising respiratory health challenges.
Sanofi has received FDA breakthrough therapy designation for Wayrilz to treat warm autoimmune hemolytic anemia, a rare disorder with no approved targeted therapies. Japan has also granted orphan status.
.jpeg)
MedGenome launches MetaSeq, an advanced blood test using NGS to detect 1,400+ pathogens in just five days, offering faster, more accurate diagnosis for bloodstream infections.
.png)
Pfizer’s Hympavzi (marstacimab) has received FDA Priority Review for treating haemophilia A or B patients aged 6 and older with inhibitors, as well as paediatric patients (ages 6-11) without inhibitors.
.png)
Lupin Pharmaceuticals has officially launched its epilepsy drug, Lacosamide, in the U.S., offering a new treatment option for adults with partial-onset seizures. This generic version of Vimpat is approved by the FDA and strengthens Lupin’s U.S. portf
.jpg)
.jpg)
, CDSCO.jpg)